China SXT Pharmaceuticals (STU:2RY) Debt-to-EBITDA : 0.00 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is China SXT Pharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

China SXT Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.00 Mil. China SXT Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.00 Mil. China SXT Pharmaceuticals's annualized EBITDA for the quarter that ended in Sep. 2024 was €-0.99 Mil. China SXT Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for China SXT Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

STU:2RY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.66 Med: -0.21 Max: 0.42
Current: 0.42

During the past 8 years, the highest Debt-to-EBITDA Ratio of China SXT Pharmaceuticals was 0.42. The lowest was -6.66. And the median was -0.21.

STU:2RY's Debt-to-EBITDA is ranked better than
73.49% of 679 companies
in the Drug Manufacturers industry
Industry Median: 1.62 vs STU:2RY: 0.42

China SXT Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for China SXT Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China SXT Pharmaceuticals Debt-to-EBITDA Chart

China SXT Pharmaceuticals Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-EBITDA

Get a 7-Day Free Trial

-6.67

-0.02

-0.41

-0.72

-1.13

China SXT Pharmaceuticals Semi-Annual Data
	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Debt-to-EBITDA	Get a 7-Day Free Trial											-0.60	-0.45	-0.17	0.19	-

Competitive Comparison of China SXT Pharmaceuticals's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China SXT Pharmaceuticals's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where China SXT Pharmaceuticals's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

China SXT Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

China SXT Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.165	+	0.271)	/	-2.163
	=	-1.13

China SXT Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-0.994
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2024) EBITDA data.

China SXT Pharmaceuticals (STU:2RY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

China SXT Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of China SXT Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

China SXT Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China SXT Pharmaceuticals Inc (STU:2RY) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

SXTC:USA

Address

No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300

Website

http://www.sxtchina.com

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

China SXT Pharmaceuticals Headlines

No Headlines